国务院常务会议解读｜规范生物医学新技术应用 助力健康中国建设

Core Viewpoint - The State Council's executive meeting approved the draft regulation for the management of clinical research and application of new biomedical technologies, aiming to promote innovation and development in China's biomedical technology sector [1] Group 1: Regulation and Development - The regulation aims to accelerate the research and application of biomedical technologies, enhancing the quality and upgrading the biomedical industry [1] - It emphasizes the importance of balancing development and safety, ensuring that clinical research is conducted legally and that the quality and safety of clinical applications are guaranteed [1] Group 2: Industry Implications - The regulation is expected to facilitate medical advancements while ensuring the safety and quality of healthcare, thereby protecting human dignity and health [1] - By clarifying the responsibilities of research institutions, enterprises, and medical organizations, the regulation aims to strengthen risk warning and emergency management, marking a significant step towards modernizing governance in this field [1]